BridgeBio Pharma (BBIO) Q2 FY26 earnings call

BridgeBio Pharma reported a strong Q2 FY26, driven by continued commercial momentum for Attruby, which saw significant growth in the treatment-naive segment and new clinical differentiation data. The company also advanced all three late-stage pipeline programs into regulatory review, securing priority designations for two, and bolstered its financial position with a $1 billion equity financing. While the Attruby switch market normalizes and combination therapy for ATTR-CM faces setbacks, BridgeBio is poised for multiple product launches and sustained growth, focusing on clinical differentiatio